Shield Therapeutics PLC Additional Listing (7598X)
May 01 2019 - 5:58AM
UK Regulatory
TIDMSTX
RNS Number : 7598X
Shield Therapeutics PLC
01 May 2019
Shield Therapeutics plc
("Shield" or the "Group")
Additional Listing
London, UK, 1(st) May 2019: Shield Therapeutics plc (LSE:STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with or without anaemia via its lead product
Feraccru(R), announces that it issued and allotted 47,169 Ordinary
Shares of 1.5p each following the exercise of options under the
Shield Therapeutics Retention Share Plan.
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on 8 May 2019. The Ordinary Shares shall
rank pari passu with the existing ordinary shares in the
Company.
Following admission, the Company's issued share capital will
comprise 117,088,657 ordinary Shares and each Ordinary Share
carries one vote. There are no Ordinary Shares held in treasury and
accordingly, the total number of voting rights is 117,088,657. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
- Ends -
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive
Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial Officer
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7841 917
Paul McManus / Helen Cresswell 679
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, pharmaceutical company
delivering innovative specialty pharmaceuticals to address
patients' unmet medical needs. The Company's clear purpose is to
help its patients become people again, by enabling them to enjoy
the things that make the difference in their everyday lives. The
Group has a marketed product, Feraccru(R), for the treatment of
iron deficiency in adults which has exclusive IP rights until the
mid-2030s. Feraccru(R) is commercialised in the European Union by
Norgine BV and the US Food and Drug Administration (FDA) is
currently considering a New Drug Application (NDA), with a PDUFA
(Prescription Drug User Fee Act) date of 27(th) July 2019. For more
information please visit www.shieldtherapeutics.com.
About Feraccru(R)
Feraccru(R) is a novel, stable, non-salt based oral treatment
for adults with iron deficiency with or without anaemia that has
been shown to be an efficacious and well-tolerated therapy in a
range of controlled phase 3 trials. Following the recently
announced(1) positive results of the Phase IIIb AEGIS-H2H study in
which Feraccru(R) demonstrated it was non-inferior to
intravenously-administered Ferinject(R) at delivering improvements
in haemoglobin levels without requiring hospital-based
administration, Feraccru(R) offers a compelling alternative to IV
Iron for those patients that cannot tolerate salt-based oral iron
therapies and wish to avoid the complexities of infusion-based
therapies.
When salt-based oral iron therapies are ingested they can cause
a range of mild-to-severe gastrointestinal tract (GI) adverse
events, including nausea, bloating and constipation. These lead to
poor tolerability, reduced patient compliance and ultimately
treatment failure. Feraccru(R) is not an iron salt; iron can be
absorbed from the ferric maltol molecule and, as a result, it does
not routinely cause the same treatment-limiting intolerance
issues.
Prior to Feraccru(R), IV iron therapies were the only realistic
alternative treatment option for patients intolerant of or
unwilling to take salt-based oral iron therapies. However, use of
such an invasive, costly, inconvenient and complex to administer
treatment option, which is associated with potentially
life-threatening and spontaneous hypersensitivity reactions, means
there remains a clear unmet medical need for patients with iron
deficiency with or without anaemia to have access to an effective
therapy like Feraccru(R) that is well tolerated, convenient and
does not require hospital-based administration.
Feraccru(R) is approved and marketed in the European Union for
the treatment of iron deficiency with or without anaemia in adults
and in Switzerland for the treatment of iron deficiency anaemia in
adults with IBD.
About Iron Deficiency
The WHO state that ID is the most common and widespread
nutritional disorder in the world. As well as affecting a large
number of children and women in non-industrialized countries, it is
the only nutrient deficiency which is also significantly prevalent
in virtually all industrialized nations. There are no current
global figures for ID, but using anaemia as an indirect indicator
it can be estimated that most preschool children and pregnant women
in non-industrialized countries, and at least 30-40% in
industrialized countries, are iron deficient.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements. These forward-looking statements are based on
management's current expectations and include statements related to
the timing of future results of Feraccru trials and the timing and
success of the Group's regulatory plans and commercial strategy for
Feraccru. These statements are neither promises nor guarantees, but
involve known and unknown risks and uncertainties, many of which
are beyond our control, that may cause actual results, performance
or achievements to be materially different from management's
expectations expressed or implied by the forward-looking
statements, including, but not limited to, risks associated with
the regulatory approval process, the Group's business and results
of operations, competition and other market factors. The
forward-looking statements made in this press release represent
management's expectations as of the date of this press release, and
except as required by law, the Group disclaims any obligation to
update any forward-looking statements contained in this release,
even if subsequent events cause our views to change.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ALSKMGGKGMDGLZM
(END) Dow Jones Newswires
May 01, 2019 06:58 ET (10:58 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024